Hunger in humans induced by MK-329, a specific peripheral-type cholecystokinin receptor antagonist
- PMID: 2378921
- DOI: 10.1016/0006-3223(90)90635-f
Hunger in humans induced by MK-329, a specific peripheral-type cholecystokinin receptor antagonist
Similar articles
-
The role of cholecystokinin in interleukin-1-induced anorexia.Physiol Behav. 1993 Aug;54(2):237-41. doi: 10.1016/0031-9384(93)90105-o. Physiol Behav. 1993. PMID: 8372116
-
Regulation of pancreatic endocrine function by cholecystokinin: studies with MK-329, a nonpeptide cholecystokinin receptor antagonist.J Clin Endocrinol Metab. 1990 May;70(5):1312-8. doi: 10.1210/jcem-70-5-1312. J Clin Endocrinol Metab. 1990. PMID: 2186058 Clinical Trial.
-
Endogenous cholecystokinin reduces vocalization in isolated 10-day-old rats.Behav Neurosci. 1993 Jun;107(3):488-92. doi: 10.1037//0735-7044.107.3.488. Behav Neurosci. 1993. PMID: 8329138
-
[Cholecystokinin antagonists: anxiolytic drugs of the future].Pathol Biol (Paris). 1992 Mar;40(3):215-7. Pathol Biol (Paris). 1992. PMID: 1608663 Review. French. No abstract available.
-
[Cholecystokinin and its antagonists: effects on digestive motility].Gastroenterol Clin Biol. 1991;15(10):744-57. Gastroenterol Clin Biol. 1991. PMID: 1816015 Review. French. No abstract available.
Cited by
-
Appetite- and Weight-Regulating Neuroendocrine Circuitry in Hypothalamic Obesity.Endocr Rev. 2024 May 7;45(3):309-342. doi: 10.1210/endrev/bnad033. Endocr Rev. 2024. PMID: 38019584 Free PMC article. Review.
-
Satiety effects of a physiological dose of cholecystokinin in humans.Gut. 1995 Feb;36(2):176-9. doi: 10.1136/gut.36.2.176. Gut. 1995. PMID: 7883212 Free PMC article.
-
2-Naphthalenesulphanyl-L-aspartyl-2-(phenethyl) amide (2-NAP) and food intake in rats: evidence that endogenous peripheral CCK does not play a major role as a satiety factor.Br J Pharmacol. 1995 Nov;116(5):2371-4. doi: 10.1111/j.1476-5381.1995.tb15082.x. Br J Pharmacol. 1995. PMID: 8581271 Free PMC article.
-
Effect of a low dose of intraduodenal fat on satiety in humans: studies using the type A cholecystokinin receptor antagonist loxiglumide.Gut. 1994 Apr;35(4):501-5. doi: 10.1136/gut.35.4.501. Gut. 1994. PMID: 8174988 Free PMC article. Clinical Trial.
-
Immunoglobulin-like domain containing receptor 1 mediates fat-stimulated cholecystokinin secretion.J Clin Invest. 2013 Aug;123(8):3343-52. doi: 10.1172/JCI68587. Epub 2013 Jul 25. J Clin Invest. 2013. PMID: 23863714 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources